Related Experiment Video
Updated: Apr 20, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Novel chemotherapeutic approaches in adult high-grade gliomas
Justin T Jordan1, Patrick Y Wen
1Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, 450 Brookline Avenue, Boston, MA, 02215, USA.
Abstract:
Despite decades of advancing science and clinical trials, average survival remains dismal for individuals with high-grade gliomas. Our understanding of the genetic and molecular aberrations that contribute to the aggressive nature of these tumors is continually growing, as is our ability to target such specific traits. Herein, we review the major classes of such targeted therapies, as well as the relevant clinical trial outcomes regarding their efficacy.
Insights
Targeted therapies show promise for high-grade gliomas, but survival remains poor. This review examines current targeted treatments and their clinical trial results for aggressive brain tumors.
Area of Science:
- Neuro-oncology
- Molecular biology
- Clinical pharmacology
Background:
- High-grade gliomas are aggressive brain tumors with historically poor patient survival rates.
- Despite scientific advancements, significant challenges remain in effectively treating these malignancies.
- Growing knowledge of glioma genetics and molecular pathways offers new therapeutic avenues.
Purpose of the Study:
- To review major classes of targeted therapies for high-grade gliomas.
- To summarize clinical trial outcomes evaluating the efficacy of these targeted treatments.
- To provide an overview of the current landscape of precision medicine in glioma treatment.
Main Methods:
- Literature review of targeted therapies for high-grade gliomas.
- Analysis of published clinical trial data on treatment efficacy.
- Synthesis of information on genetic and molecular aberrations driving glioma progression.
Main Results:
- Several classes of targeted therapies have been developed, including those targeting specific genetic mutations and signaling pathways.
- Clinical trial results demonstrate varying degrees of efficacy, with some agents showing modest improvements in progression-free survival.
- Challenges such as tumor heterogeneity and resistance mechanisms impact overall treatment effectiveness.
Conclusions:
- Targeted therapies represent a significant advancement in the management of high-grade gliomas.
- Further research is needed to overcome treatment resistance and improve long-term patient outcomes.
- Personalized treatment strategies based on molecular profiling are crucial for optimizing glioma therapy.
